gliclazide and Diabetic Angiopathies studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Research Excerpts

Excerpt	Relevance	Reference
"We conducted a population-based cohort study of patients aged 66 years and older who were hospitalized for acute myocardial infarction or who underwent percutaneous coronary intervention between 1 April 2007 and 31 March 2010 while receiving either glyburide or gliclazide."	3.78	Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. ( Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR, 2012)
"In patients with type 2 diabetes, moderate alcohol use, particularly wine consumption, is associated with reduced risks of cardiovascular events and all-cause mortality."	2.79	The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. ( Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."	2.73	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
"The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments."	2.42	Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004)
"Gliclazide is a second-generation sulfonylures that is widely used in the treatment of non-insulin-dependent diabetes mellitus (Type 2 diabetes)."	2.39	[Gliclazide: review of metabolic and vascular action]. ( Alberti, KG, 1994)
"Gliclazide is a second-generation sulfonylurea that is widely used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)."	2.38	Gliclazide: metabolic and vascular effects--a perspective. ( Alberti, KG; Johnson, AB; Taylor, R, 1992)
"Gliclazide is an oral sulfonylurea agent that has been reported to have actions on platelet function and fibrinolysis in addition to its effects on glycemia."	2.38	Pathophysiology of vascular disease in diabetes: effects of gliclazide. ( Colwell, JA, 1991)
"Treatment with glyburide significantly reduced aggregation in response to 10 microM of epinephrine and collagen at 750 microgram/ml."	2.36	Sulfonylureas and platelet function. ( Jackson, WP; Jacobs, P; Kernoff, L; Klaff, LJ; Vinik, AI, 1981)
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues."	1.51	Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019)
"In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae."	1.42	Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015)
"Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring."	1.35	Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009)
"The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops."	1.30	Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. ( Muggeo, M, 1998)

Research

Studies (42)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (9.52)	18.7374
1990's	15 (35.71)	18.2507
2000's	11 (26.19)	29.6817
2010's	12 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Mohammedi, K	2
Woodward, M	9
Marre, M	4
Colagiuri, S	1
Cooper, M	5
Harrap, S	6
Mancia, G	6
Poulter, N	8
Williams, B	3
Zoungas, S	8
Chalmers, J	10
Huang, HK	1
Yeh, JI	1
Abdelmoneim, AS	2
Eurich, DT	1
Gamble, JM	1
Johnson, JA	1
Seubert, JM	1
Qiu, W	2
Simpson, SH	2
Konig, M	1
Lamos, EM	1
Stein, SA	1
Davis, SN	1
Blomster, JI	1
Li, Q	2
Chow, CK	1
Neal, B	6
Patel, A	8
Hillis, GS	1
Hirakawa, Y	2
Arima, H	1
Ninomiya, T	2
Hamet, P	4
Huang, Y	1
Light, P	1
Kengne, AP	1
Matthews, DR	1
Grobbee, R	1
Jardine, M	1
MacMahon, S	3
Billot, L	1
Glasziou, P	2
Grobbee, D	2
Heller, S	3
Liu, L	2
Mogensen, CE	1
Pan, C	2
Rodgers, A	1
Bompoint, S	1
de Galan, BE	3
Joshi, R	1
Travert, F	3
Cass, A	1
Lisheng, L	2
Pillai, A	2
Perkovic, V	1
Anderson, C	1
Dufouil, C	1
Grobbee, DE	1
Hackett, M	1
Heller, SR	1
Pan, CY	1
Kassem, SA	1
Raz, I	1
Bloomgarden, Z	1
Januszewicz, A	1
Tandon, N	1
Joshi, P	1
Avogaro, A	1
Juurlink, DN	1
Gomes, T	1
Shah, BR	1
Mamdani, MM	1
Chaturvedi, V	1
Currie, R	1
Monaghan, H	1
Schernthaner, G	1
Belcher, G	1
Lambert, C	1
Goh, KL	1
Edwards, G	1
Valbuena, M	1
Sena, CM	1
Louro, T	1
Matafome, P	1
Nunes, E	1
Monteiro, P	1
Seiça, R	1
Velikov, VK	1
Shubina, IO	1
Saltykov, BB	1
Frolova, AI	1
Klaff, LJ	1
Kernoff, L	1
Vinik, AI	1
Jackson, WP	1
Jacobs, P	1
Lesobre, B	3
Jennings, PE	2
Alberti, KG	2
O'Brien, RC	1
Luo, M	1
Cathelineau, G	1
de Champvallins, M	1
Bouallouche, A	1
Muggeo, M	1
Giulietti, M	1
Cho, YW	1
Yang, DH	1
Oh, DY	1
Baick, SH	1
Kim, SK	1
Kim, SJ	1
Hong, SY	1
Gram, J	1
Jespersen, J	1
Johnson, AB	1
Taylor, R	1
Ziegler, O	1
Drouin, P	1
Colwell, JA	1
Marquié, G	1
Hadjiisky, P	1
Arnaud, O	1
Duhault, J	1
Barnett, AH	1
Larkins, RG	1
Jerums, G	1
Taft, JL	1
Godfrey, H	1
Smith, IL	1
Martin, TJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]	Phase 3	11,140 participants (Actual)	Interventional	2001-06-30	Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]		150 participants (Anticipated)	Interventional	2016-11-30	Active, not recruiting
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]		200 participants (Anticipated)	Observational	2012-01-31	Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]		160 participants (Actual)	Interventional	2013-12-31	Active, not recruiting
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]	Phase 4	135 participants (Actual)	Interventional	2016-10-31	Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]	Phase 3	104 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]		465 participants (Actual)	Interventional	2015-08-31	Completed
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]		8,494 participants (Actual)	Observational	2010-01-31	Completed
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]	Phase 2	20 participants (Actual)	Interventional	2014-04-30	Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]		0 participants (Actual)	Interventional	2011-09-30	Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	kg (Mean)
Insulin Glargine, Metformin, Exenatide	-4.8
Insulin Glargine, Metformin, Prandial Insulin	0.7

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	µg/ml (Median)
Sitagliptin	0
Gliclazide	8.4

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmol/L (Median)
Sitagliptin	-0.2
Gliclazide	-0.1

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmHg (Median)
Sitagliptin	4
Gliclazide	-9

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	mmol/L (Median)
Sitagliptin	0.1
Gliclazide	-0.1

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	score on a scale (Median)
Sitagliptin	3
Gliclazide	1.8

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	score on a scale (Median)
Sitagliptin	9.5
Gliclazide	9.4

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Intervention	kg (Median)
Sitagliptin	-0.5
Gliclazide	-0.6

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

Intervention	dCt (Median)
Gliclazide	-1.12
Sitagliptin	0

Intervention	dCt (Median)
Sitagliptin	3.41
Gliclazide	2.09

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

Intervention	pg/ml (Median)
Sitagliptin	-0.07
Gliclazide	0.43

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	Participants (Count of Participants)
Sitagliptin	6
Gliclazide	10

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

Intervention	score on a scale (Median)
	DLQI	HAQ-8	HADS Anxiety	HADS Depression	EQ-5D
Gliclazide	-1.0	0.0	0	0	-0.2
Sitagliptin	0.0	0.0	-1	0	0

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

Article	Year
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Current diabetes reviews, 2013, Volume: 9, Issue:5 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ	2013
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Administration, Oral; Cardiovascular Diseases; Diabetic Angiopathies; Disease Progression; Enzyme In	2009
Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 1 Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne	2012
Diabetes and vascular disease: a new international trial. Asian cardiovascular & thoracic annals, 2003, Volume: 11, Issue:2 Topics: Antihypertensive Agents; Developing Countries; Diabetes Complications; Diabetes Mellitus; Diabetic A	2003
Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:8 Suppl 1 Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration S	2003
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. International journal of clinical practice, 2004, Volume: 58, Issue:9 Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glicl	2004
Sulfonylureas and platelet function. The American journal of medicine, 1981, Volume: 70, Issue:3 Topics: Adenosine Diphosphate; Blood Glucose; Blood Platelets; Collagen; Diabetes Mellitus; Diabetic Angiopa	1981
[Non-insulin dependent diabetes. Role of gliclazide (diamicron)]. Journees annuelles de diabetologie de l'Hotel-Dieu, 1995 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gliclazide; Humans; Male	1995
[Gliclazide: review of metabolic and vascular action]. Diabete & metabolisme, 1994, Volume: 20, Issue:3 Pt 2 Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Gliclazide; Glucose; Humans	1994
Vascular benefits of gliclazide beyond glycemic control. Metabolism: clinical and experimental, 2000, Volume: 49, Issue:10 Suppl 2 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Glic	2000
Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients. Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1 Topics: Arteriosclerosis; Diabetes Mellitus; Diabetic Angiopathies; Fibrinolysis; Gliclazide; Humans	1992
Gliclazide: metabolic and vascular effects--a perspective. Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Insul	1992
Hemobiological activity of gliclazide in diabetes mellitus. Diabetes research and clinical practice, 1991, Volume: 14 Suppl 2 Topics: Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Platelet Adhe	1991
Pathophysiology of vascular disease in diabetes: effects of gliclazide. The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A Topics: Arteriosclerosis; Blood Platelets; Diabetic Angiopathies; Endothelium, Vascular; Gliclazide; Humans	1991
Pathogenesis of diabetic microangiopathy: an overview. The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A Topics: Basement Membrane; Diabetic Angiopathies; Endothelium, Vascular; Free Radicals; Gliclazide; Hemostas	1991
[Macroangiopathy and type 2 diabetes mellitus: significance of Diamicron]. Journees annuelles de diabetologie de l'Hotel-Dieu, 1990 Topics: Animals; Arteriosclerosis; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endoth	1990

Article	Year
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. Diabetes care, 2014, Volume: 37, Issue:5 Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabet	2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat	2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat	2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat	2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat	2014
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes. Diabetes care, 2016, Volume: 39, Issue:12 Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea	2016
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes care, 2009, Volume: 32, Issue:11 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose;	2009
Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes care, 2011, Volume: 34, Issue:12 Topics: Aged; Asia; Australia; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Euro	2011
The potential of gliclazide, a sulphonylurea to influence the oxidative processes within the pathogenesis of diabetic vascular disease. Advances in experimental medicine and biology, 1994, Volume: 366 Topics: Adult; Aged; Analysis of Variance; Animals; Blood Glucose; Diabetic Angiopathies; Free Radical Scave	1994
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study. Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1 Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St	1997
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia, 2001, Volume: 44, Issue:9 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Diabetes Mellitus, Type 2; Diabe	2001
Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study. Diabetes research and clinical practice, 1988, Jan-07, Volume: 4, Issue:2 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie	1988

Article	Year
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovascular diabetology, 2017, 07-27, Volume: 16, Issue:1 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Fem	2017
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. Diabetes research and clinical practice, 2019, Volume: 152 Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio	2019
Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:1 Topics: Acute Coronary Syndrome; Aged; Alberta; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Typ	2014
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. Journal of diabetes and its complications, 2015, Volume: 29, Issue:2 Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular	2015
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3 Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat	2016
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2009, Volume: 52, Issue:11 Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A	2009
Recent cardiovascular trials: what are the drivers of benefit and adverse effect? Journal of diabetes, 2009, Volume: 1, Issue:4 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemog	2009
Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:12 Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathi	2012
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiological research, 2009, Volume: 58, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab	2009
[Experience with diamicron treatment of diabetics]. Klinicheskaia meditsina, 1984, Volume: 62, Issue:11 Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Evaluation; Dru	1984
The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1 Topics: Administration, Oral; Adult; Antioxidants; Ascorbic Acid; Coronary Artery Disease; Diabetes Mellitus	1997
Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. Diabetic medicine : a journal of the British Diabetic Association, 1998, Volume: 15 Suppl 4 Topics: Amputation, Surgical; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic	1998
[Hypoglycemic agents of the 2d generation]. La Clinica terapeutica, 1978, Jul-31, Volume: 86, Issue:2 Topics: Blood Coagulation; Blood Platelets; Diabetic Angiopathies; Gliclazide; Humans; Microcirculation; Sul	1978
Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis. The Korean journal of internal medicine, 1992, Volume: 7, Issue:2 Topics: Antigens; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fibrinolys	1992
International Symposium on Diabetes, Vascular Risks, and Gliclazide (Diamicron). Washington, DC, June 28, 1991. Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1 Topics: Diabetes Mellitus; Diabetic Angiopathies; Gliclazide; Humans	1992
Development of macroangiopathy in sand rats (Psammomys obesus), an animal model of non-insulin-dependent diabetes mellitus: effect of gliclazide. The American journal of medicine, 1991, Jun-24, Volume: 90, Issue:6A Topics: Animals; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Ani	1991

gliclazide and Diabetic Angiopathies